NCT01353469 - Assessment of Efficacy and Safety of Insuman Comb 25 Versus Novolin® 30R Twice Daily Over 24 Weeks in Type 2 Diabetes Patients With Insulin Therapy | Biotech Hunter

Enrollment

485

Participants

Timeline

Start Date

May 31, 2011

Primary Completion Date

November 30, 2012

Study Completion Date

November 30, 2012

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG

Insulin human/Insuman Comb 25 (HR1799)

"Pharmaceutical form:Suspension~Route of administration: Subcutaneous"

DRUG

Insulin human/Novolin® 30R

"Pharmaceutical form:Suspension~Route of administration: Subcutaneous"

Trial Locations (23)

100088

Investigational Site Number 156024, Beijing

100730

Investigational Site Number 156010, Beijing

100853

Investigational Site Number 156001, Beijing

110022

Investigational Site Number 156027, Shenyang

130011

Investigational Site Number 156033, Changchun

130041

Investigational Site Number 156017, Changchun

150001

Investigational Site Number 156007, Harbin

200003

Investigational Site Number 156002, Shanghai

200040

Investigational Site Number 156023, Shanghai

200062

Investigational Site Number 156031, Shanghai

200065

Investigational Site Number 156004, Shanghai

210006

Investigational Site Number 156016, Nanjing

210011

Investigational Site Number 156018, Nanjing

215004

Investigational Site Number 156029, Suzhou

230001

Investigational Site Number 156020, Hefei

300052

Investigational Site Number 156025, Tianjin

310013

Investigational Site Number 156032, Hangzhou

400016

Investigational Site Number 156006, Chongqing

410008

Investigational Site Number 156005, Changsha

430022

Investigational Site Number 156003, Wuhan

610072

Investigational Site Number 156021, Chengdu

710032

Investigational Site Number 156008, Xi'an

710061

Investigational Site Number 156009, Xi'an